SEATTLE & CAMBRIDGE, Mass. & TOKYO, September 30, 2025--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today ...
A Delaware judge dismissed a former Aurion Biotech executive's challenge to a stockholder's alleged takeover of the company, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Earn-in: KoBold can earn an undivided 75% interest in commodities discovered in the Project Area (other than any discoveries that are predominantly gold or silver) by incurring USD$12,000,000 in ...
Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...
Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction U.S. pivotal trial to assess efficacy and ...
In making its unanimous recommendation to the Securityholders, the Board considered and relied upon a number of factors, including, among others: Agnico has entered into voting and support agreements ...
The cell-therapy startup Aurion Biotech has raised $120 million to pursue its ambition of curing blindness. The Boston and Seattle startup announced the Series C financing round on April 12, with ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results